7150-23-4
7150-23-4 結(jié)構(gòu)式
基本信息
6-甲氧基-3-吡啶甲酰胺
BUTTPARK 182\12-94
6-Methoxynicotinamide
JBSNF-000088 (JBSNF000088
6-methoxy-3-pyridinecarboxamide
6-METHOXYPYRIDINE-3-CARBOXAMIDE
3-PYRIDINECARBOXAMIDE, 6-METHOXY-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | XW02715023403 | 6-甲氧基-3-吡啶羧胺 | 7150-23-4 | 1G | 409元 |
| 2024/11/08 | S6779 | 6-甲氧基-3-吡啶羧胺 JBSNF-000088 | 7150-23-4 | 25mg | 470.74元 |
| 2024/11/08 | HY-112584 | 6-甲氧基-3-吡啶羧胺 JBSNF-000088 | 7150-23-4 | 100mg | 900元 |
常見問題列表
| Target | Value |
|
hNNMT
(Cell-free assay) | 1.8 μM |
|
mkNNM
(Cell-free assay) | 2.8 μM |
|
mNNMT
(Cell-free assay) | 5.0 μM |
JBSNF-000088 (6-Methoxynicotinamide) has IC 50 values are 1.6 and 6.3?μM for U2OS or differentiated 3T3L1 cells.
JBSNF-000088 (6-Methoxynicotinamide) (50?mg/kg; oral route of administration for four weeks) shows statistically significant reduction in body weight (%) and leads to a statistically significant reduction in fed blood glucose on day 21.
JBSNF-000088 (50?mg/kg; oral gavage administration; twice daily for four weeks) leads to a statistically significant improvement in oral glucose tolerance on day 28 with glucose tolerance being normalized.
JBSNF-000088 (1 mg/kg; intravenous administration; for 4 hours) results in low plasma clearance of 21?mL/min?kg and the volume of distribution at steady state of 0.7?L/kg, a very short plasma half-life of 0.5?hours upon intravenous administration.
JBSNF-000088 (10 mg/kg; oral gavage; for 4 hours) results in a Cmax of 3568 ng/mL with a T
max
value of 0.5?hours, indicating rapid absorption in the intestine, and half-life of 0.4?hours by oral gavage. The oral bioavailability is found to be approximately 40%.
| Animal Model: | Mice with high fat diet (HFD)-induced obesity |
| Dosage: | 50?mg/kg |
| Administration: | Oral route of administration for four weeks; oral gavage administration and twice daily for four weeks |
| Result: |
Showed statistically significant reduction in body weight (%) and led to a statistically significant reduction in fed blood glucose on day 21 by oral route of administration.
Led to a statistically significant improvement in oral glucose tolerance on day 28 with glucose tolerance being normalized by oral gavage administration. |
| Animal Model: | C57BL/6 mice |
| Dosage: | 1 mg/kg (Intravenous administration);10 mg/kg (oral gavage)(Pharmacokinetic Study) |
| Administration: | Intravenous administration and oral gavage; for 4 hours |
| Result: |
Resulted in low plasma clearance of 21?mL/min?kg and the volume of distribution at steady state of 0.7?L/kg, a very short plasma half-life of 0.5?h upon intravenous administration.
Resulted in a Cmax of 3568 ng/mL with a T max value of 0.5?hours, indicating rapid absorption in the intestine, and half-life of 0.4?hours by oral gavage. |